A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Terminated
Infinity Pharmaceuticals, Inc.
Phase 1
2011-10-01
The purpose of this study is to determine the safety, maximum tolerated dose and
pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Terminated
SecuraBio
Phase 1
2011-10-01
The purpose of this study is to determine the safety, maximum tolerated dose and
pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects
Completed
Infinity Pharmaceuticals, Inc.
Phase 2
2012-07-01
The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on lung
function in mild asthmatic subjects following allergen challenge.
A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects
Completed
SecuraBio
Phase 2
2012-07-01
The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on lung
function in mild asthmatic subjects following allergen challenge.
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Completed
Infinity Pharmaceuticals, Inc.
Phase 2
2013-04-01
The purpose of this study is to investigate the safety and efficacy of multiple dose levels
of the investigational product (study drug), IPI-145, in combination with methotrexate
compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid
Arthritis.
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Completed
SecuraBio
Phase 2
2013-04-01
The purpose of this study is to investigate the safety and efficacy of multiple dose levels
of the investigational product (study drug), IPI-145, in combination with methotrexate
compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid
Arthritis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
